Our Good News Holiday Campaign is the culmination of our year of "Time to Tell the Stories 2022." In this series, we celebrate the connections, the celebrations, the events and milestones that we’ve been privileged to be a part of this year. Jim Hughes talks about research.
Jim Hughes A National Cancer Institute team led by Paul Meltzer recently published a paper in Science and Translational Medicine entitled, “Recurrent epimutation of SDHC in gastrointestinal stromal tumors.” The findings have some potential implications [...]
ASCO was held again this year in Chicago. Over 32,000 medical professionals and exhibitors participated in what has become an international event. 53% of attendees now come from outside the US. It helps to know [...]
The phase III dose escalation study intended to answer questions about Gleevec blood levels has halted recruitment after failing to meet accrual goals, having recruited only five first-line GIST patients in 14 months. Informal discussions with Novartis Pharmaceuticals, the Sarcoma Alliance for Research through Collaboration (SARC) and the trial investigators provided some insight into the reasons for the change in status.
The heat shock chaperone protein (HSP-90) has emerged as a promising target for cancer therapy. Infinity Pharmaceuticals’ IPI-504 is one of many experimental heat shock protein inhibitors vying for a spot in the cancer market. [...]